Background {#Sec1}
==========

Osteosarcoma, the most common type of primary bone cancer, is a rare disease. Approximately 900 new cases of osteosarcoma are diagnosed each year in the United States (<http://www.cancer.org/docroot/home/index.asp>) and 200 in France, including 150 in children (<http://www.fnclcc.fr/sor/SSP/CancersEnfant/PeauTissusSoutien/Osteosarcome>). Adjuvant and neoadjuvant chemotherapy have significantly improved the long-term survival rate for patients with osteosarcoma \[[@CR1]--[@CR3]\]. Nevertheless, recurrent disease still occurs in about 30--40% of patients and more than 70% of them die of their tumor, despite second-line treatment. The standard therapy regimen of high-grade osteosarcoma includes induction by multiagent chemotherapy followed by surgical resection and postoperative chemotherapy \[[@CR4]\]. The percentage of necrotic tissue following induction chemotherapy is classified with the Huvos grading system \[[@CR5]\]. Patients with \<90% tumor necrosis following induction therapy are classified as "poor responders" (PR) or Huvos grade I/II \[[@CR6]\], while more than 90% necrosis corresponds to Huvos grade III and complete necrosis to Huvos grade IV. Good responders (GR) correspond to Huvos grade III/IV. The degree of necrosis remains the only reliable prognostic factor for the patients presenting with localized disease and is used to guide the choice of postoperative chemotherapy. Numerous clinical trials have attempted to increase the disease-free survival rate for poorly responding patients with intensified postoperative therapy. No survival benefit has been convincingly shown through the administration of more intensified therapy to poor responders \[[@CR3], [@CR7]--[@CR10]\]. This suggests that there may be an innate biological difference between good responsive and poor responsive tumors. Previous transcriptomic studies have shown that in chemoresistant tumors, the genes involved in osteoclastogenesis, extracellular matrix remodeling, bone development, tumor progression, drug resistance and angiogenesis are up-regulated \[[@CR11]--[@CR17]\]. However, none of these molecular predictive factors can be used routinely. Therefore, there is a need to establish reliable predictive biomarkers for the response to chemotherapy at the time of diagnosis. The aim of this study was to identify molecular markers expressed differentially between "good" and "poor" responders to neoadjuvant chemotherapy in order to predict the response to chemotherapy in conventional osteosarcoma before beginning treatment, and to elucidate the mechanisms involved in this response. We identified several subsets of novel potential candidate genes. In particular, our data suggest that *ERK1* and *STAT3* expression are involved in the response to chemotherapy and that they could be therapeutic targets.

Methods {#Sec2}
=======

Patients and tumor specimens {#Sec3}
----------------------------

The response to preoperative chemotherapy was assessed on resected specimens according to Rosen's protocol \[[@CR4]\]. To identify differentially expressed genes between "good" and "poor" responders (GR and PR) to chemotherapy, Suppression Subtractive Hybridization (SSH) was performed by using cDNA from frozen biopsy specimens taken for diagnosis prior to treatment. SSH was performed by using 5 samples of GR patients (three males and two females, mean age 14 years) and 4 samples of PR patients (two males and two females, mean age 13.5 years). All patients received preoperative and postoperative chemotherapy derived from the SFOP OS 94 regimen \[[@CR18]\]. Clinicopathological characteristics of the patients studied by SSH are presented in Table [1](#Tab1){ref-type="table"}. The two groups were similar in tumor volume, tumor location and histological subtype. Expression of selected relevant genes identified by SSH was validated by using real-time quantitative RT-PCR (QRT-PCR). For QRT-PCR, the same specimens and additional specimens of 22 patients were obtained. The whole cohort consisted of 13 GR and 18 PR. Immunohistochemistry (IHC) was performed on Tissue Microarray (TMA) sections consisting of 52 biopsies of patients with a conventional osteosarcoma. Six of 9 samples used for SSH were used for TMA. 18 of the 31 samples used in QRT-PCR were used for TMA. In total, among the 52 patients in the TMA validation cohort, only 5 received chemotherapy without high-dose MTX. The vast majority of patients (40) were those treated according to protocol OS94 or by neoadjuvant chemotherapy with methotrexate, vepeside and ifosfamide. All samples were obtained after informed consent from patients or their parents when the patients were under the age of 18.Table 1**Clinicopathological characteristics of the 9 patients studied by SSH**Good respondersPoor respondersNumber of patients54Mean age at diagnosis \[95% IC\] (years)14 \[5-17\]13.5 \[13-16\]SexMale32Female22Tumor location Upper limb21 Lower limb33Histological subtype Osteoblastic43 Osteoblastic and chondroblastic11Mean tumor size \[95% IC\] (cm)12.5 \[8-34\]9 \[6.7-25\]Mean viable residual tumor cells \[95% IC\] (%)2.5 \[1-4.5\]25 \[17-37\]

Research involving the patients have been performed with the approval of Protection of the Person Center: CPP sud Méditerranée 1 ethics committee (authorization number: DC-2008-309) in compliance with the Helsinki Declaration. Samples were from a tumor bank that respects the ethical charter of the French National Cancer Institute (AP-HM Biobank authorization number 2013-1786).

*RNA*preparation {#Sec4}
----------------

Total RNA extraction was performed from frozen tumor specimens by using the acid guanidinium isothiocyanate/phenol/chloroform procedure. Before use, RNA samples were treated with 10U ribonuclease-free deoxyribonuclease (Promega, France) at 37°C for 15 min. Tests for purity and quality were performed on a nanodrop spectrophotometer and the Agilent 2100 Bioanalyser RNA LabChip kit (Agilent Technologies, Palo Alto, CA, USA) \[[@CR19], [@CR20]\]. Only samples with RNA integrity Number (RIN) \> 7 and no evidence of ribosomal degradation were included.

SMART-Suppression Subtractive Hybridization (SMART: "switching mechanism at 5' end of the RNA transcript") {#Sec5}
----------------------------------------------------------------------------------------------------------

Poly(A) + mRNA were isolated from GR and PR total RNA using an Oligotex mRNA isolation kit (Qiagen, France) and gene expression between these two mRNA populations was compared by SMART-SSH using a Super PCR cDNA Synthesis Kit for cDNA synthesis (Clontech) and a PCR-Select cDNA subtraction kit (Clontech), a principle previously described by Diatchenko et al. \[[@CR21]\].

Cloning and analysis of subtracted clones {#Sec6}
-----------------------------------------

Products from the final PCR amplification were cloned into a Topo TA cloning vector (Invitrogen Life Technologies, France) and electro-transferred into One Shot *E. coli*. Differential screening was performed to eliminate false positives. Hybridizations were performed in duplicate according to standard procedures. Specific clones were prepared by using a Qiagen plasmid mini-kit and sequenced (QIAGEN France SAS, Coutaboeuf, France). Nucleic acid homology searches were carried out with the BLAST program at the NCBI, USA.

Quantitative Reverse Transcription Polymerase Chain Reaction (QRT-PCR) {#Sec7}
----------------------------------------------------------------------

QRT-PCR was used to accurately detect the changes of expression of selected relevant genes: *ERK1* and *STAT3* gene expression levels and ribosomal 18S RNA as reference sequence. Total RNA (1 μg) DNA-free was reverse-transcribed into cDNA using hexamers (Pharmacia Biotech, Orsay, France) and Superscript II Reverse Transcriptase (Invitrogen Life Technologies, France). Genes of interest and *18S* rRNA were amplified, detected and quantified in real-time by using the Light Cycler Real-Time PCR (Roche Applied Science, Meylan, France). QRT-PCR was performed by using the oligonucleotides and sequence parameters described in Table [2](#Tab2){ref-type="table"} in a medium containing 1X LightCycler 480 SYBR Green I master mix, 0.25 μM of each primer and 20 ng of cDNA. Each PCR reaction was preceded by one activation cycle of 95°C for 5 min and ended by establishing a melting curve 5 degrees above the oligonucleotide melting temperature.Table 2**Description of oligonucleotides and sequence parameters for QRT-PCR**Name geneOligo directOligo reversePCR conditionsCycle numberGeneInfo identifier*18S*CTACCACATCCAAGGAAGGCATTTTTCGTCACTACCTCCCCG95°C 15 sec3512451765967°C 30 sec*ERK1*CTAAAGCCCTCCAACCTGCTCAGCCCACAGACCAGATGT95°C 15 sec4515813850660°C 30 sec*STAT3*AAAGTCAGGTTGCTGGTCAAATGCCGTTGTTGGATTCTTC95°C 15 sec457625392760°C 30 sec

Immunohistochemistry (IHC) on tissue microarray sections (TMA) {#Sec8}
--------------------------------------------------------------

Automated immunohistochemistry was performed on slides of TMA paraffin blocks. The 52 tumor specimens were all fixed in 4% formalin. Fleshy tissue was separated from calcified areas to avoid unnecessary decalcification. When necessary, tumor specimens were decalcified in a solution of 22% formic acid. TMA were prepared as previously described \[[@CR20]\]. For each sample, three representative sample areas were carefully selected from a hematoxylin--eosin-stained section of a donor block. Core cylinders with a diameter of 1 mm each were punched from three representative areas and deposited onto two separate recipient paraffin blocks by using a specific arraying device (Alphelys). To determine the expression of activated forms of STAT3 and ERK1 proteins, we used anti-phospho-STAT3 (Tyr705) (polyclonal, 9131 from Cell Signaling Technology, dilution 1/20) and anti-phospho-ERK1 (polyclonal, clone 20G11 from Cell Signaling Technology, dilution: 1/100) antibodies. Automated IHC was performed with a Ventana automate (Benchmark XT, Ventana Medical Systems SA, Illkirch, France). Positive external control was a glioblastoma for both pSTAT3 and pERK1. Negative controls were also included and corresponded to omission of primary antibody or irrelevant antibodies of the same isotype. IHC was scored positive when nuclear staining was observed. A semi-quantitative analysis was done for positive specimens without knowledge of clinical data. Percentage of stained cells and staining intensity (weak, moderate, high) were taken into account to obtain the score. Score 0 was attributed to tumors with absence of staining. Score 1 was attributed to tumors with low intensity of staining whatever the number of stained nuclei or to tumors with no more than 25% of nuclei immunostained with moderate intensity. Score 2 corresponded to stained nuclei numbering between 25% and 50% with moderate intensity or to fewer than 25% of stained nuclei with high intensity. Score 3 was defined as either more than 50% of stained nuclei with moderate intensity or more than 25% of stained nuclei with high staining intensity. A mean score was proposed for the three areas of each tumor. Three independent observers evaluated the IHC results blind to clinical data. A consensus score was reached and statistical analysis was performed from the consensus score.

Data analysis {#Sec9}
-------------

Relationships between response to chemotherapy (GR vs. PR) and other parameters used were obtained by using non-parametric tests, the Fisher exact test and the Mann-Whitney test when qualitative and continuous respectively. All tests were two-sided. P-value was considered significant when ≤ 5%. SAS System version 9.2 (SAS Institute Inc., Cary, NC) and Stata software (version 10.1 Special Edition, StataCorp, College Station, Texas) were used to perform data analyses.

Results {#Sec10}
=======

Patients {#Sec11}
--------

Clinicopathological characteristics of the patients studied are presented in Table [3](#Tab3){ref-type="table"}.Table 3**Clinicopathological characteristics of the 52 patients studied by IHC including those studied by SSH and QRT-PCR**Whole cohortNumber of patients52AgeMean age at diagnosis \[95% IC\]^a^ (years)17.4 \[5;80\]SexMale (%)34 (65.4)Female (%)18 (34.6)Histologic response Good responders24 Poor responders28Histological diagnosis and subtypeHigh-grade osteosarcomas of central "conventional" type52 Osteoblastic (%)38 (73) Chondroblastic (%)5 (9.5) Telangiectasic (%)3 (6) Fibroblastic (%)2 (4) Mixed subtype^b^ (%)4 (7.5)^a^Confidence Interval, for the whole cohort, to ascertain that the screening cohort is a representative subset of the whole.^b^Osteoblastic and chondroblastic or fibroblastic.

Identification of differentially expressed genes by SSH in PR {#Sec12}
-------------------------------------------------------------

A subtractive cDNA library of PR was generated. 126 selected clones were sequenced (Table [4](#Tab4){ref-type="table"}). The following genes were selected on the basis of their known roles in tumorigenesis or chemoresistance: *ACTN1, AKT2, ANXA2, CADM1, CDKN2C(P18), FN1, GAL1, HRAS, IGFBP3, LMNA, ERK1* and *STAT3*. Particularly, *STAT3* is a key factor for chemosensitivity in human epithelial ovarian cancer cells and thyroid cancer-derived CD133+ cells \[[@CR22]--[@CR24]\]. Recent studies show that ERKs may also be activated in response to chemotherapeutic drugs, and pERK1/2 played critical roles in drug resistance \[[@CR25]--[@CR28]\]. Thus, these selected genes were tested by QRT-PCR.Table 4**Identification of genes differentially expressed by SSH in PR**Gene titleGene symbolChromosomal locationActin, alpha 1, skeletal muscleACTA1chr1q42.13-q42.2Actin, betaACTBchr7p15-p12Actin, gamma 1ACTG1chr17q25Actinin, alpha 1ACTN1chr14q24.1-q24.2\|14q24\|14q22-q24ADAM metallopeptidase with thrombospondin type 1 motif, 20ADAMTS20chr12q12v-akt murine thymoma viral oncogene homolog 2AKT2chr19q13.1-q13.2Ankyrin repeat domain 11ANKRD11chr16q24.3Annexin A2ANXA2chr15q21-q22AT rich interactive domain 4B (RBP1-like)ARID4Bchr1q42.1-q43Actin-related protein 2/3 complex, subunit 2, 34 kDaARPC2chr2q36.1ATPase family, AAA domain containing 3AATAD3Achr1p36.33ATP synthase, H + transporting, mitochondrial F0 complex, subunit E///major facilitator superfamily domain containing 7ATP5I///MFSD7chr4p16.3Bromo adjacent homology domain containing 1BAHD1chr15q15.1Breast carcinoma amplified sequence 3BCAS3chr17q23Branched chain aminotransferase 2, mitochondrialBCAT2chr19q13Chromosome 14 open reading frame 112C14orf112chr14q24.2Chromosome 14 open reading frame 2C14orf2chr14q32.33Chromosome 20 open reading frame 194C20orf194chr20p13Cell adhesion molecule 1CADM1chr11q23.2Coiled-coil domain containing 28BCCDC28Bchr1p35.1Chaperonin containing TCP1, subunit 8 (theta)CCT8chr21q22.11Cell division cycle 34 homolog (S. cerevisiae)CDC34chr19p13.3Cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4)CDKN2Cchr1p32Carbohydrate (chondroitin 4) sulfotransferase 11CHST11chr12qCreatine kinase, brainCKBchr14q32CDC28 protein kinase regulatory subunit 1BCKS1Bchr1q21.2CLPTM1-likeCLPTM1Lchr5pter-p15.3CornifelinCNFNchr19q13.2Collagen, type V, alpha 1COL5A1chr9q34.2-q34.3Catechol-O-methyltransferaseCOMTchr22q11.21-q11.23\|22q11.21Cytochrome c oxidase subunit VIa polypeptide 1COX6A1chr12q24.2\|12q24.2Cytokine receptor-like factor 1CRLF1chr19p12Chondroitin sulfate glucuronyltransferaseCSGlcA-Tchr7q36.1Casein kinase 2, alpha prime polypeptideCSNK2A2chr16q21cutA divalent cation tolerance homolog (E. coli)CUTAchr6pter-p21.31dodecenoyl-Coenzyme A delta isomerase (3,2 trans-enoyl-Coenzyme A isomerase)DCIchr16p13.3Dicarbonyl/L-xylulose reductaseDCXRchr17q25.3DEAD (Asp-Glu-Ala-As) box polypeptide 19ADDX19Achr16q22.1DEAD (Asp-Glu-Ala-As) box polypeptide 19B///DEAD (Asp-Glu-Ala-As) box polypeptide 19ADDX19A///DDX19Bchr16q22.1DEAD (Asp-Glu-Ala-Asp) box polypeptide 39DDX39chr19p13.12Eukaryotic translation elongation factor 1 delta (guanine nucleotide exchange protein)EEF1Dchr8q24.3Eukaryotic elongation factor-2 kinaseEEF2Kchr16p12.1Eukaryotic translation initiation factor 3, subunit HEIF3Hchr8q24.11Eukaryotic translation initiation factor 4 gamma, 3EIF4G3chr1p36.12Fas apoptotic inhibitory molecule 3FAIM3chr1q32.1FK506 binding protein 7FKBP7chr2q31.2Kappa-actinFKSG30chr2q21.1Flavin containing monooxygenase 5FMO5chr1q21.1Fibronectin 1FN1chr2q34FERM domain containing 5FRMD5chr15q15.3Golgi SNAP receptor complex member 2GOSR2chr17q21Glypican 1GPC1chr2q35-q37G protein-coupled receptor 108GPR108chr19p13.3Ribosomal protein L23a///similar to ribosomal protein L23A///ribosomal protein L23a-likehCG_16001///hCG_2001000///RPL23Achr17q11///chr17q23.2///chr3q26.1v-Ha-ras Harvey rat sarcoma viral oncogene homologHRASchr11p15.5Heparan sulfate proteoglycan 2HSPG2chr1p36.1-p34Insulin-like growth factor 2 mRNA binding protein 3IGF2BP3chr7p11Inositol(myo)-1(or 4)-monophosphatase 2IMPA2chr18p11.2Integrator complex subunit 1INTS1chr7p22.3Importin 11IPO11chr5q12.1Jumonji domain containing 2CJMJD2Cchr9p24.1KIAA0999 proteinKIAA0999chr11q23.3Laminin, alpha 4LAMA4chr6q21Lectin, galactoside-binding, soluble, 1 (galectin 1)LGALS1chr22q13.1Lamin A/CLMNAchr1q21.2-q21.3Ribosomal protein S16///similar to 40S ribosomal protein S16LOC441876///RPS16chr19q13.1///chr1p36.21Leucine-rich repeat containing 28LRRC28chr15q26.3Microtubule-associated protein 1SMAP1Schr19p13.11Mitogen-activated protein kinase 3MAPK3 (ERK1)chr16p11.2Major facilitator superfamily domain containing 5MFSD5chr12q13.13Mitochondrial ribosomal protein S7MRPS7chr17q25NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4, 9 kDaNDUFA4chr7p21.3NADH dehydrogenase (ubiquinone) Fe-S protein 7, 20 kDa (NADH-coenzyme Q reductase)NDUFS7chr19p13.3NADH dehydrogenase (ubiquinone) flavoprotein 1, 51 kDaNDUFV1chr11q13Nuclear factor I/C (CCAAT-binding transcription factor)NFICchr19p13.3NOL1/NOP2/Sun domain family, member 5NSUN5chr7q11.23NOL1/NOP2/Sun domain family, member 5BNSUN5Bchr7q11.23NOL1/NOP2/Sun domain family, member 5CNSUN5Cchr7q11.23Nucleoporin 214 kDaNUP214chr9q34.1Nucleoporin 85 kDaNUP85chr17q25.1PDZ domain containing 2PDZD2chr5p13.3PeriplakinPPLchr16p13.3Protein phosphatase 1, regulatory (inhibitor) subunit 12BPPP1R12Bchr1q32.1Protein phosphatase 2 (formerly 2A), regulatory subunit A, alpha isoformPPP2R1Achr19q13.33Protein kinase C substrate 80 K-HPRKCSHchr19p13.2Protein arginine methyltransferase 2PRMT2chr21q22.3RNA binding protein, autoantigenic (hnRNP-associated with lethal yellow homolog (mouse))RALYchr20q11.21-q11.23RNA binding motif protein 4RBM4chr11q13RNA binding motif protein 4BRBM4Bchr11q13RNA binding motif protein 8ARBM8Achr1q12Ribosomal protein L13RPL13chr16q24.3\|17p11.2Ribosomal protein L13aRPL13Achr19q13.3Ribosomal protein L19RPL19chr17q11.2-q12Ribosomal protein L23aRPL23Achr17q11Ribosomal protein L31RPL31chr2q11.2Ribosomal protein, large, P1RPLP1chr15q22Ribosomal protein S12RPS12chr6q23.2Ribosomal protein S14RPS14chr5q31-q33Ribosomal protein S17RPS17chr15qRibosomal protein S21RPS21chr20q13.3Ribosomal protein S27 (metallopanstimulin 1)RPS27chr1q21Ribosomal protein S6RPS6chr9p21RNA pseudouridylate synthase domain containing 4RPUSD4chr11q24.2Ribosomal RNA processing 1 homolog B (S. cerevisiae)RRP1Bchr21q22.3Retinoid X receptor, alphaRXRAchr9q34.3Synaptonemal complex protein SC65SC65chr17q21.2Splicing factor, arginine/serine-rich 3SFRS3chr6p21Serine hydroxymethyltransferase 2 (mitochondrial)SHMT2chr12q12-q14SIVA1, apoptosis-inducing factorSIVA1chr14q32.33SIVA1, apoptosis-inducing factorSIVA1chr14q32.33Solute carrier family 16, member 8 (monocarboxylic acid transporter 3)SLC16A8chr22q12.3-q13.2Solute carrier family 20 (phosphate transporter), member 2SLC20A2chr8p12-p11Small nuclear ribonucleoprotein D3 polypeptide 18 kDaSNRPD3chr22q11.23Signal transducer and activator of transcription 3 (acute-phase response factor)STAT3chr17q21.31Serine/threonine kinase 24 (STE20 homolog, yeast)STK24chr13q31.2-q32.3T-cell, immune regulator 1, ATPase, H + transporting, lysosomal V0 subunit A3TCIRG1chr11q13.2Testis-specific kinase 1TESK1chr9p13Thymosin, beta 10TMSB10chr2p11.2Transportin 3TNPO3chr7q32.1Tetraspanin 9TSPAN9chr12p13.33-p13.32Ubiquitin A-52 residue ribosomal protein fusion product 1UBA52chr19p13.1-p12Vacuolar protein sorting 28 homolog (S. cerevisiae)VPS28chr8q24.3Williams-Beuren syndrome chromosome region 16WBSCR16chr7q11.23WW domain containing oxidoreductaseWWOXchr16q23.3-q24.1X antigen family, member 1D///X antigen family, member 1C///X antigen family, member 1E///X antigen family, member 1///X antigen family, member 1BXAGE1///XAGE1B///XAGE1C///XAGE1D///XAGE1EchrXp11.22Zinc finger protein 449ZNF449chrXq26.3

QRT-PCR validation of selected genes expressed in PR versus GR by SSH {#Sec13}
---------------------------------------------------------------------

Only *STAT3* mRNA level and *ERK1* mRNA level were significantly different between PR and GR. Quantification of *STAT3* and *ERK1* mRNA transcripts revealed higher mRNA levels in PR compared to GR samples (p = 0.019 and p = 0.046 respectively). The mean level of *STAT3* mRNA was 0.820 \[0.280-13.970\] in PR versus 0.310 \[0.230-2.370\] in GR samples (Figure [1](#Fig1){ref-type="fig"}A) and the mean level of *ERK1* was 0.270 \[0.110-4.340\] in PR versus 0.150 \[0.088-0.710\] in GR samples (Figure [1](#Fig1){ref-type="fig"}B).Figure 1**RTQ-PCR analysis of STAT3 and ERK1 genes. A**: Quantification of STAT3 mRNA with 18S rRNA reference gene transcript confirmed higher STAT3 mRNA levels in poor responder (PR) samples compared with good responder (GR) samples (p = 0.019). **B**: Quantification of MAPK3 (ERK1) mRNA with 18S rRNA reference gene transcript confirmed higher MAPK3 (ERK1) mRNA levels in PR samples compared with GR samples (p = 0.046).

Validation at protein level using immunohistochemistry for pSTAT3 and pERK1 (Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}) {#Sec14}
--------------------------------------------------------------------------------------------------------------------------------------------------

pSTAT3 nuclear expression was examined in 45 cases out of 52 and a high score was observed in 20 cases (score 2 and 3). pERK1 expression was examined in 45 cases out of 52 (low score in 25 cases and high score in 20 cases) (Figure [2](#Fig2){ref-type="fig"}). pSTAT3 protein expression was correlated to poor response to chemotherapy for a percentage of viable residual cells ≤10%, with the higher scores in the PR group (p = 0.036). A statistically significant correlation was also found between pERK1 protein expression and response to chemotherapy when comparing low scores (0-1) versus high scores (2-3) (p = 0.007). Moreover, the correlation between the expression of pSTAT3 and pERK1 in IHC and the response to chemotherapy remained statistically significant for patients under 25 years (p = 0.024 and p = 0.010 respectively). For a percentage of viable residual cells lower than 5%, a statistically significant correlation was still found between pSTAT3 or pERK1 protein expression and response to chemotherapy (p = 0.013 and p = 0.035 respectively). Whatever the threshold (5 or 10%), positive predictive value (probability of belonging to the group of PR in case of high score) of both pSTAT3 and pERK1 in combination was 91%. Negative predictive value (probability of belonging to the group of GR in case of low score) of both pSTAT3 and pERK1 in combination for a 5 and 10% threshold were 69% and 75% respectivelyTable 5**Correlation between phosphorylated STAT3 and ERK1 IHC expression to poor response to chemotherapy for a percentage of viable residual cells ≤10%**IHC scoreGood respondersPoor respondersp-valuePhosphorylated STAT30 or 11690.0362 or 3614VPP~(PR)~ = 14/20 = 70%/VPN~(GR)~ = 16/25 = 64%Phosphorylated ERK10 or 11780.0072 or 3515VPP~(PR)~ = 15/20 = 75%/VPN~(GR)~ = 17/25 = 68%Phosphorylated STAT3 and ERK1Both 0-11240.003Intermediate87Both 2-3110VPP~(both/PR)~ = 10/11 = 91%/VPN~(both/GR)~ = 12/16 = 75%Table 6**Correlation between phosphorylated STAT3 and ERK1 IHC expression to poor response to chemotherapy for a percentage of viable residual cells lower than 5%**IHC scoreGood respondersPoor respondersp-valuePhosphorylated STAT30 or 113120.0132 or 3317VPP~(PR)~ = 17/20 = 85%/VPN~(GR)~ = 13/25 = 52%Phosphorylated ERK10 or 113120.0352 or 3416VPP~(PR)~ = 16/20 = 80%/VPN~(GR)~ = 13/25 = 52%Phosphorylated STAT3 and ERK1Both 0-11150.007Intermediate510Both 2-3110VPP~(both/PR)~ = 10/11 = 91%/VPN~(both/GR)~ = 11/16 = 69%Figure 2**IHC pSTAT3 scores.** Score 0: negative staining (X200). Score 1: *\>50% of nuclei* are labeled with low staining intensity (X200). Score 2: \<50% cells with moderate staining intensity and \<25% of cells are highly stained (X200). Score 3: more than 50% of nuclei are stained with moderate staining intensity (X200).

Discussion {#Sec15}
==========

SSH is a molecular biology technique that enables the identification of differentially expressed genes between two groups with high sensitivity. By comparing PR to GR prior to chemotherapy among patients with an osteosarcoma, we found 126 clones. *ERK1* and *STAT3*, the genes selected on the basis of their roles in tumorigenesis or chemoresistance, were further studied by QRT-PCR in an independent cohort. *ERK1* and *STAT3* expressions assessed by QRT-PCR and IHC were significantly linked to the response to chemotherapy. The protein encoded by *ERK1* is a member of the MAP kinase family and acts in a signalling cascade that regulates various cellular processes such as proliferation, differentiation, and cell cycle progression in response to a variety of extracellular signals. We found ERK1/2 positivity score by IHC and ERK1/2 IHC high score (score 2 and 3) in 78% and 51% of our cohort, respectively. These results suggested that ERK1/2 pathway could be involved in osteosarcoma as it has supported by Pignochino et al. study that showed activated ERK 1/2 pathway in 66.6% of osteosarcoma samples. Moreover, the same team also showed that Sorafenib, a tyrosine kinase inhibitor, blocks tumor growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of *ERK1/2* \[[@CR29]\]. No attempt to investigate the link between *ERK1* expression and response to chemotherapy was made in vivo. However, our work suggested that *ERK1* could be involved in drug resistance as reported recently by Si et al. with an approach by RNAi-mediated knockdown of *ERK1/2* inhibiting cell proliferation and invasion and increasing chemosensitivity to cisplatin in human osteosarcoma U2-OS cells in vitro \[[@CR30]\].

*STAT3* is one of the transcription factors reported to play an important role in tumor survival, proliferation, angiogenesis and metastasis. In normal cells, *STAT3* is activated transiently to maintain homeostasis. However, if *STAT3* continues to be activated, the abnormal level of expression can trigger oncogenic pathways. Aberrant active *STAT3* promotes uncontrolled growth and survival through dysregulation of expression of downstream targeted genes including *survivin*, *Bcl-xL*, *Bcl-2*, *Mcl-1*, *c-Myc* and *cyclin D1*. Constitutive activation of the STAT3 pathway has recently been shown in several malignancies, especially osteosarcoma \[[@CR31]\]. It has recently been implicated in resistance to chemotherapy-induced apoptosis \[[@CR32]\]. Furthermore, activation of *STAT3* in several cancers has been found to be correlated with clinical outcome especially in osteosarcoma. A high level of expression of STAT3 by IHC in 76 biopsies of patients with an osteosarcoma was a poor prognostic factor for both overall survival and disease-free survival in univariate and multivariate analysis \[[@CR33]\]. High staining with pSTAT3 was also of prognostic value in another series of 51 conventional osteosarcomas \[[@CR34]\]. In addition, inhibition of *STAT3* plays a role in proliferation, apoptosis and migration in osteosarcoma cells in vitro. The down-regulation of *STAT3* by miR-125b suppresses in vitro proliferation and migration of osteosarcoma cells \[[@CR35]\]. *STAT3* inhibition by RNA interference induces inhibition of proliferation and apoptosis enhancement in osteosarcoma cells \[[@CR33]\]. The novel curcumin analog FLLL32 decreases *STAT3* DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines \[[@CR36]\]. The small molecules, LLL12 and FLLL32, inhibit *STAT3* phosphorylation and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice \[[@CR37]\]. In contrast, oncostatin M promotes *STAT3* activation, VEGF production, and invasion in osteosarcoma cell lines \[[@CR38]\]. Finally, *STAT3* is involved in drug resistance in osteosarcoma cell lines. Ryu et al. recently showed that the STAT3 pathway was overexpressed in MDR osteosarcoma cells and that inhibitors of *STAT3* such as CDDO-Me could reduce resistance to doxorubicin in these cell lines \[[@CR31]\]. In our study, we have showed an expression of pSTAT3 in 58% of cases. This activated STAT3 pathway was correlated to poor response to chemotherapy. Thus, our results are consistent with the results of the literature in vitro through the analysis of patient samples.

The effects of *EGFR* are mediated by activation of downstream signal transduction cascades that include Janus tyrosine kinases (*Jak*), Signal Transducers and Activators of Transcription (*STAT*), Phophatidyl Inositol 3 Kinase (*PI3K*)/Akt and Ras/RAf/MAP kinase (*ERK*). The prognostic value of *EGFR* and its downstream signaling molecules such as STAT3 and ERK1 have been studied in many tumor types. Only one study \[[@CR39]\] simultaneously examined the status of *EGFR* and four downstream molecules - pSTAT3, pERK1, pAkt, survivin - by IHC in 47 samples of conventional osteosarcomas. *ERK1* and *survivin* expression were statistically correlated with survival. A high expression was negatively correlated with prognosis. Furthermore, *EGFR* expression was correlated with expression of *ERK1* and it was observed a significant association of *survivin* expression with *STAT3* and *ERK* activation. These results and ours support the idea that ERK is a downstream signaling molecule of EGFR and also suggest a link between the EGFR signaling pathway and drug resistance through *ERK1* and *STAT3* expression in conventional osteosarcoma.

Conclusions {#Sec16}
===========

We have shown that high pSTAT3 and pERK1 expression in the biopsies are suggestive of poor response to chemotherapy. The elevated positive predictive value of high score of both pSTAT3 and pERK1 in combination (91%) highly suggests that IHC test could be used at the time of diagnosis to stratifying patients enrolled in randomized trials. Our results also suggest that *STAT3* and *ERK1* inhibitors might be used in combination with common chemotherapeutic drugs in osteosarcoma in order to increase the response to chemotherapy and to improve the prognosis. Finally, other genes identified by SSH remain to be explored and a prospective validation phase on a larger cohort is still needed before these biomarkers could be used in clinical practice.
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